DEFINIUM THERAPEUTICS, INC.
DFTXLoading price...
Overview
Previous Close44.49
Open44.98
Ask45.00
Bid32.04
Day's Range42.84 - 45.00
52 Week Range8.59 - 49.20
PE Ratio(TTM)--
Market Cap5.78B
Volume1.96M
Avg. Volume2.8M
12 Months Earnings-237.54M
12 Months Revenue0.00
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 193.37M | 166.31M | 103.92M | 93.87M | 66.33M |
| Profit after Tax (Net Income) | -237.54M | -183.79M | -108.68M | -95.73M | -56.80M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: New York, United States
Website: https://definiumtx.com
CEO & Director: Mr. Robert Barrow
Employees: 105
About Company:
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.